CFO Capital Management LLC Invests $563,000 in Labcorp Holdings Inc. $LH

CFO Capital Management LLC acquired a new stake in Labcorp Holdings Inc. (NYSE:LH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,245 shares of the medical research company’s stock, valued at approximately $563,000.

Several other hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC purchased a new stake in Labcorp during the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Labcorp in the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the fourth quarter valued at approximately $27,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp during the 4th quarter worth approximately $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

LH has been the subject of several recent research reports. Wall Street Zen cut shares of Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Piper Sandler lifted their target price on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Finally, Robert W. Baird set a $334.00 target price on Labcorp in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $308.00.

Insider Buying and Selling

In other news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the sale, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.84% of the company’s stock.

Labcorp Stock Up 0.1%

Labcorp stock opened at $255.96 on Friday. The stock has a market cap of $20.99 billion, a PE ratio of 22.67, a P/E/G ratio of 1.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The stock’s fifty day moving average is $261.33 and its two-hundred day moving average is $265.50. Labcorp Holdings Inc. has a 1-year low of $241.81 and a 1-year high of $293.72.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts expect that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s payout ratio is presently 25.51%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.